Natriuretic peptides - Relevance in cardiovascular disease

JAMA

Volumn 280, Issue 23, 1998, Pages 1983-1984

  Cheung, Bernard M Y ^a   Kumana, Cyrus R ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b JAMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NATRIURETIC FACTOR;

CARDIOVASCULAR DISEASE; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN FAMILY; SHORT SURVEY;

EID: 0032539160     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.280.23.1983     Document Type: Short Survey

References (23)

1. Nakao K, Ogawa Y, Suga S, Imura H. Molecular biology and biochemistry of the natriuretic peptide system. J Hypertens. 1992;10:907-912.
2. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321-328.
3. de Bold AJ, Bruneau BG, Kuroski de Bold ML. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res. 1996;31:7-18.
4. Lang CC, Choy AJ, Struthers AD. Atrial and brain natriuretic peptides. Clin Sci. 1992;83:519-527.
5. La Villa G, Padeletti L, Lazzeri C, et al. Plasma levels of natriuretic peptides during ventricular pacing in patients with a dual chamber pacemaker. Pacing Clin Electrophysiol. 1994;17:953-958.
6. Cheung BMY, Dickerson JEC, Ashby MJ, Brown MJ, Brown J. Effects of physiological increments in human alpha-atrial natriuretic peptide and human brain natriuretic peptide in normal male subjects. Clin Sci. 1994;86:723-730.
7. Maack T, Suzuki M, Almeida FA, et al. Physiological role of silent receptors of atrial natriuretic factor. Science. 1987;238:675-678.
8. Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C. Renal, endocrine and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab. 1993;76:91-96.
9. Cody RJ, Atlas SA, Laragh JH, et al. Atrial natriuretic factor in normal subjects and heart failure patients. J Clin Invest. 1986;78:1362-1374.
10. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. Circulation. 1996;94:3184-3189.
11. Choy AJ, Darbar D, Lang CC, et al. Detection of left ventricular dysfunction after acute myocardial infarction. Br Heart J. 1994;72:16-22.
12. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet. 1994;343:440-444.
13. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 1998;351:9-13.
14. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997;350:1349-1351.
15. Yamamoto K, Burnett JC Jr, Jougasaki M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension. 1996;28:988-994.
16. Cheung BMY. Plasma concentration of brain natriuretic peptide is related to diastolic dysfunction in hypertension. Clin Exp Pharmacol Physiol. 1997; 24:966-968.
17. Arakawa N, Nakamura M, Aoki H, Hiramori K. Relationship between plasma level of brain natriuretic peptide and myocardial infarct size. Cardiology. 1994;85:334-340.
18. Omland T, Aakvaag A, Bonarjee WS, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Circulation. 1996;93:1963-1969.
19. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure. Circulation. 1997;96:509-516.
20. Wallen T, Landahl S, Hedner T, Nakao K, Saito Y. Brain natriuretic peptide predicts mortality in the elderly. Heart. 1997;77:264-267.
21. Northridge DB, Jardine AG, Findlay IN, et al. Inhibition of the metabolism of atrial natriuretic factor causes diuresis and natriuresis in chronic heart failure. Am J Hypertens. 1990;3:682-687.
22. Bevan EG, Connell JMC, Doyle J, et al. Candoxatril, a neutral endopeptidase inhibitor. J Hypertens. 1992;10:607-613.
23. Tunny TJ, Ziesak MD, Armstrong R, et al. Inhibition of endopeptidase EC 3.4.24.11 by candoxatril lowered blood pressure and increased urinary but not plasma atrial natriuretic peptide in essential hypertension. J Hypertens. 1993;11(suppl 5):S222-S223.